Amicus Therapeutics (NASDAQ:FOLD) Earns Daily News Sentiment Rating of -0.05

Press coverage about Amicus Therapeutics (NASDAQ:FOLD) has been trending somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of -0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 48.364673594047 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research firms have issued reports on FOLD. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. J P Morgan Chase & Co restated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Chardan Capital restated a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Goldman Sachs Group restated a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. Finally, Leerink Swann restated a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $17.81.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down $0.29 on Friday, reaching $13.63. The company had a trading volume of 2,013,253 shares, compared to its average volume of 1,955,269. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 1 year low of $4.41 and a 1 year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. During the same period last year, the firm earned ($0.33) EPS. The company’s revenue was up 419.0% compared to the same quarter last year. equities analysts forecast that Amicus Therapeutics will post -1.56 EPS for the current year.

In related news, insider Hung Do sold 50,194 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $715,264.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daphne Quimi sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $99,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 628,224 shares of company stock valued at $9,024,003. 3.40% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics (NASDAQ:FOLD) Earns Daily News Sentiment Rating of -0.05” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/02/amicus-therapeutics-fold-earning-somewhat-negative-press-coverage-report-shows.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply